One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
BioAtla logo
BioAtla BCAB
$ 1.74 0.64%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

BioAtla Financial Statements 2025-2011 | BCAB

Annual Financial Statements BioAtla

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

9.41 M 7.77 M 144 M 98.5 M 224 M 949 M - - - - - - - - -

Shares

58.8 M 48.6 M 47.8 M 38.9 M 34.6 M 21.6 M - - - - - - - - -

Historical Prices

0.16 0.16 3.01 2.53 6.48 53.1 - - - - - - - - -

Net Income

-59.6 M -69.8 M -123 M -106 M -95.4 M -35.9 M -29.8 M -29 M - - - - - - -

Revenue

- - - - 300 K 429 K 5.2 M 10.6 M - - - - - - -

Gross Profit

- - - - - 429 - - - - - - - - -

Operating Income

-59.3 M -73.9 M -130 M -108 M -96.4 M -30.1 M -28.3 M - - - - - - - -

Interest Expense

-302 K 4.17 M 6.22 M 1.66 M 3 K 1.39 M 1.63 M - - - - - - - -

EBITDA

-58.9 M -73 M -128 M -107 M -95.1 M -29.1 M -27.4 M -27.4 M - - - - - - -

Operating Expenses

61.3 M 84.9 M 130 M 108 M 96.7 M 30.5 M 33.5 M 38.9 M - - - - - - -

General and Administrative Expenses

17.7 M 21.8 M 26 M 28.8 M 38.4 M 10.6 M 7.55 M 12.6 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement BioAtla

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.17 M 1.5 M - 58.7 M 58.5 M 58.2 M 58.1 M 48.3 M 48.2 M 48.1 M 48.1 M 47.8 M 47.7 M 47.6 M 46.3 M 37.5 M 37.4 M 37.3 M 35.8 M 33.9 M 33.7 M 33.6 M 32.2 M 80.9 M 32.2 M 32.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-18.7 M -6.34 M - -15.8 M -18.7 M -15.3 M - -10.6 M -21.1 M -23.2 M - -33.3 M -35.8 M -27.5 M - -25.8 M -28.9 M -24.3 M - -22.9 M -30.4 M -18.7 M - -11.6 M -6.22 M -1.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - - - - - - - - - - - - - - 300 K 300 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-18.6 M -9.31 M - -13.8 M -18.6 M -17.6 M - -11.3 M -22 M -24.5 M - -35 M -37.2 M -28.9 M - -26.2 M -29.1 M -24.3 M - -23.7 M -30.5 M -18.8 M - -8.02 M -4.52 M -1.11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-64 K 2.96 M - -1.99 M -64 K 2.28 M - 684 K 900 K 1.22 M - 1.7 M 1.45 M 1.47 M - 400 K 149 K 92 K - 3 K 1 K 2 K - 86 K 754 K 547 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-18.6 M -9.19 M - - - -17.4 M - - - -24.2 M - - - -28.6 M - -25.3 M -28.5 M -24 M - -22.7 M -29.8 M -18.5 M - -7.3 M -4.09 M -893 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

18.6 M 9.31 M - 13.8 M 18.6 M 17.6 M - 22.3 M 22 M 24.5 M - 35 M 37.2 M 28.9 M - 26.2 M 29.1 M 24.3 M - 23.7 M 30.7 M 18.8 M - 8.16 M 4.71 M 1.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.96 M 4.73 M - 4.25 M 4.96 M 5.26 M - 5.88 M 5.77 M 5.6 M - 6.62 M 6.24 M 7.23 M - 6.34 M 8.34 M 7.42 M - 7.14 M 15.9 M 8.37 M - 3.3 M 1.79 M 463 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements BioAtla BCAB
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting BioAtla plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Magenta Therapeutics Magenta Therapeutics
MGTA
- -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
- - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
- 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
- 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
- -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
- - $ 1.2 B australiaAustralia
BiomX BiomX
PHGE
$ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
- -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
- - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
- -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
- 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
- - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
- -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
- - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
- - $ 2.64 M usaUSA
Sensei Biotherapeutics Sensei Biotherapeutics
SNSE
- - $ 17.5 M usaUSA
Sonnet BioTherapeutics Holdings Sonnet BioTherapeutics Holdings
SONN
- - $ 826 K usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Synlogic Synlogic
SYBX
- - $ 7.07 M usaUSA
Virios Therapeutics, LLC Virios Therapeutics, LLC
VIRI
- 2710.01 % $ 72.9 M usaUSA
Vallon Pharmaceuticals Vallon Pharmaceuticals
VLON
- -6.47 % $ 5.76 M usaUSA
Vaxart Vaxart
VXRT
- -25.06 % $ 46.3 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
- - $ 485 M usaUSA
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Exicure Exicure
XCUR
$ 1.12 0.88 % $ 7.05 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.04 1.36 % $ 104 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.8 2.51 % $ 3.52 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 55.9 0.22 % $ 7.48 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.68 1.65 % $ 10.5 B usaUSA